ReviewFrontiers in transplantation2026
Graft quality assessment during machine perfusion in liver transplantation: a review of current evidence and emerging strategies.
Review in Frontiers in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Machine perfusion (MP) has transformed liver transplantation by enabling organ reconditioning, extending preservation times, and providing a dynamic platform for graft quality assessment. The ability to evaluate organ viability represents one of the most clinically impactful applications of this technology. As different perfusion modalities develop, distinct strategies have emerged to characterize graft viability. However, despite the growing evidence, significant heterogeneity remains in the parameters and thresholds employed, varying between each MP modality, as well as between centers. This review provides a comprehensive and critical synthesis of available evidence on viability assessment during each perfusion modality, and discusses promising new strategies in the race to the holy grail of viability assessment: prevention of both primary non-function (PNF) as well as the prediction of ischemic cholangiopathy (IC), so as to achieve tangible benefits in patient-centered outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.